



Gentris Shanghai - A Subsidiary of CGI

Enabling Genomic Innovation in China

Creating Long Term Value for Biorepository and Pharmacogenomic Testing

CGI is a leading global provider of pharmacogenomic (PGx) testing and biorepository services for clinical trials. Located in Research Triangle Park, NC, the company has built on over 15 years of excellence in genomic medicine to establish a CLIA and CAP compliant laboratory in Zhangjiang Hi-Tech Park, Shanghai, China. Because clinical biospecimens cannot leave the country, CGI Shanghai provides pharmaceutical clients with PGx testing and sample storage solutions for all phases of clinical development, including China-specific and integrated global studies. CGI Shanghai offers a platform to advance personalized medicine and drug development in one of the fastest growing markets.

As drug developers increasingly conduct large trials that span the globe, CGI Shanghai solves a critical need for U.S. quality PGx testing and clinical sample storage in China. China has been a primary focus in recent years due to a rapidly growing economy and tremendous investments in pharmaceutical, biotechnology, and innovation infrastructure. CGI Shanghai provides the necessary services and expertise to conduct PGx-enabled clinical trials in China and accelerate drug development globally. By working with Chinese officials, scientific leaders, and industry partners, CGI Shanghai can also facilitate collaborations with U.S. and E.U. partners to create joint translational research projects that will drive new discoveries and better targeting of drugs for the Chinese patient population.

Enabling Genomic Innovation in China

CGI Shanghai takes pride in its renowned expertise with all major genomic platforms and has gained abundant experience with a great variety of therapeutic areas. CGI Shanghai strategically gates in key services in order to meet client demand. Biorepository services provide the following offerings:

- Sample management and tracking
- Nucleic acid extraction and purification
- Clinical sample storage
- Genotyping
- Array technology
- Sanger Sequencing

CGI Shanghai benefits from the coordination between the U.S. and Chinese sites to provide seamless, high-quality, global PGx solutions for all phases of clinical trials.

- Passed global pharma audits
- Completed Phase III trial
- Anticipate CAP accreditation 2016

Gentris Shanghai

- A CGI Subsidiary

Research Collaborations

Sponsors will be intimately involved in the development and design of research collaborations to ensure project milestones and endpoints align with their strategic objectives. Ultimately, these partnerships can lead to new innovations and genomic biomarkers that will drive value in the global marketplace.

At a Glance - Gentris Shanghai

- Business license obtained in May 2012
- Biorepository launch 2013
- Genotyping launch 2014
- 2,800 sq. ft. facility
- Located in Zhangjiang Hi-Tech Park Incubator
- CLIA, GCLP compliant
- Follows ICH E15 guidelines

For more information, contact:

Gentris Shanghai - A CGI Subsidiary

781 Cai Lun Road, Rm. 803
Shanghai 201203, P.R. China
For BD inquiries, call 1.805.368.6934

www.cancergenetics.com



v.5.3.16